Ipratropium Bromide Online
How and where to order Ipratropium Bromide (Atrovent) inhalation aerosol 20 mcg / dose online on AsthmAction website:
|Prices:||from $65.00 per bottle
|Discount:||10% coupon: MSD10
|Forms:||Inhalation spray 20 mcg / dose, 200 doses in bottle
|Quantity:||1, 3, 6 inhalers
|Type:||Atrovent generic, Ipravent brand
|Payment:||PayPal, Mastercard, AmEx, E-Check (ACH), Bitcoin
|Delivery:||Regular airmail, express courier
|Shipping:||Worldwide, including USA, UK, Europe, Canada, Australia
Ipratropium Bromide (trade names include Atrovent, Ipravent, Atrovent-Nasal, Aerovent, Aerotrop, Atrovent-N, Alovent, Atrovent HFA, Itrop, Atrovent-LS, Rinatec) is a bronchodilator medication from anticholinergics pharmacological group. This medicine is indicated for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Also it used to treat and prevent bronchial asthma (alone or in combination with other inhaled antiasthmatic drugs), to reduce rhinorrhea (in form of nasal spray). Ipratropium Bromide works by helping open up the airways in your lungs to make it easier to breathe.
Aclidinium Bromide (Tudorza Pressair)
Albuterol, Ipratropium Bromide (Combivent)
Albuterol/Salbutamol (Ventolin Inhaler, Volmax-CR)
Fluticasone, Salmeterol (Advair Diskus, Seroflo)
Glycopyrronium Bromide (Robinul)
Ipratropium Bromide, Fenoterol (Berodual-N)
Oxitropium Bromide (Oxivent)
Tiotropium Bromide (Spiriva)
Tiotropium Bromide, Formoterol Fumarate (Duova)
Umeclidinium Bromide (Incruse Ellipta)
Pharmacological and medical categories:
Antiasthmatic and COPD preparations
Medications for diseases of respiratory tract
Nasal decongestants and other nasal preparations
R - Respiratory system
R01 - Nasal preparations
R01A - Decongestants and other nasal preparations for topical use
R01AX - Other nasal preparations
R01AX03 - Ipratropium Bromide
R03 - Drugs for obstructive airway diseases
R03B - Other drugs for obstructive airway diseases, inhalants
R03BB - Anticholinergics
R03BB01 - Ipratropium Bromide
Other and unspecified disorders of nose and nasal sinuses - J34
Other specified disorders of nose and nasal sinuses - J34.89
Simple and mucopurulent chronic bronchitis - J41
Unspecified chronic bronchitis - J42
Emphysema - J43
Other chronic obstructive pulmonary disease - J44
Asthma - J45
Status asthmaticus - J46
Indications and usage:
Atrovent HFA (Ipratropium Bromide) is an anticholinergic indicated for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This medication is used to relieve the symptoms of lung disease such as asthma or chronic obstructive bronchitis. It may be used in other conditions where breathing is difficult, such as after surgery or
during assisted ventilation.
Atrovent (Ipratropium Bromide) nasal spray is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older.
Dosage and administration:
Atrovent HFA: for oral inhalation only. Two inhalations four times a day, not to exceed 12 inhalations in 24 hours.
Atrovent nasal spray 0.06% for symptomatic relief of rhinorrhea associated with the common cold: the recommended dose is two sprays (84 mcg) per nostril three or four times daily (total dose 504 to
672 mcg/day) in adults and children age 12 years and older.
Atrovent nasal spray 0.06% for symptomatic relief of rhinorrhea associated with seasonal allergic rhinitis: the recommended dose is two sprays (84 mcg) per nostril four times daily (total dose 672 mcg/day) in adults and children age 5 years and older.
Dosage forms and strengt:
Atrovent HFA (Ipratropium Bromide) inhalation aerosol: each actuation delivers 17 mcg of ipratropium bromide from mouthpiece. Supplied in a 12.9 g canister containing 200 actuations.
Atrovent (Ipratropium Bromide) nasal spray 0.06% is supplied in a white high density polyethylene (HDPE) bottle fitted with a metered nasal spray pump, a green safety clip to prevent accidental discharge of the spray, and a clear plastic dust cap. It contains 16.6 g of product formulation, 165 sprays, each delivering 42 mcg of ipratropium bromide per spray (70 mcL), or 10 days of therapy at the maximum recommended dose (two sprays per nostril four times a day).
Atrovent HFA (Ipratropium Bromide) inhalation aerosol: acute overdose by inhalation is unlikely since ipratropium bromide is not well absorbed systemically after inhalation or oral administration.
Atrovent (Ipratropium Bromide) nasal spray 0.06%: acute overdosage by intranasal administration is unlikely since ipratropium bromide is not well absorbed systemically after intranasal or oral administration. Following administration of a 20 mg oral dose (equivalent to ingesting more than two bottles of this medicine) to 10 male volunteers, no change in heart rate or blood pressure was noted.
Atrovent HFA (Ipratropium Bromide) inhalation aerosol: hypersensitivity to atropine or any of its derivatives, ipratropium bromide or other Atrovent HFA components.
Atrovent (Ipratropium Bromide) nasal spray 0.06%: in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients.
Warnings and precautions:
Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response.
Hypersensitivity reactions including anaphylaxis: discontinue Atrovent at once and consider alternative treatments.
Paradoxical bronchospasm: discontinue Ipratropium Bromide and consider other treatments if paradoxical bronchospasm occurs.
Ocular effects: use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if signs or symptoms of narrow-angle glaucoma develop.
Urinary retention: use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to consult a physician immediately if signs or symptoms of urinary retention develop.
Adverse reactions, side effects:
Most common adverse reactions ( > 5% incidence in the 12-week placebo-controlled trials) of Atrovent were bronchitis, COPD exacerbation, dyspnea, and headache.
To report suspected side effects of Atrovent (Ipratropium Bromide) inhalation aerosol and nasal spray contact Boehringer Ingelheim pharmaceutical company, or your local FDA.
Anticholinergics: may interact additively with concomitantly used anticholinergic medications. Avoid administration of Atrovent (Ipratropium Bromide) with other anticholinergic-containing drugs.
Patient counseling information:
Appropriate and safe use of Atrovent HFA (Ipratropium Bromide) includes providing the patient with the information listed below and an understanding of the way it should be administered.
Advise patients that Atrovent HFA is a bronchodilator for the maintenance treatment of bronchospasm associated with COPD and is not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response.
Inform patients that hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema, may occur after the administration of ipratropium bromide. Advise patients to immediately discontinue Atrovent HFA and consult a physician.
Inform patients that this drug can produce paradoxical bronchospasm that can be life-threatening. If paradoxical bronchospasm occurs, patients should discontinue using Atrovent HFA.
Caution patients to avoid spraying the aerosol into their eyes and be advised that this may result in precipitation or worsening of narrow-angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Patients should also be advised that should any combination of these symptoms develop, they should consult their physician immediately.
Since dizziness, accommodation disorder, mydriasis, and blurred vision may occur with use of Ipratropium Bromide (Atrovent HFA), patients should be cautioned about engaging in activities requiring balance and visual acuity such as driving a car or operating appliances or machinery.
Inform patients that this medication may cause urinary retention and should be advised to consult their physicians if they experience difficulty with urination.
Frequency of use
The action of Atrovent HFA should last 2 to 4 hours. Advise patients not to increase the dose or frequency of ipratropium bromide without patients consulting their physician. Advise patients to seek immediate medical attention if treatment with this medicine becomes less effective for symptomatic relief, their symptoms become worse, and/or patients need to use the product more frequently than usual.
Concomitant drug use
Advise patients on the use of Atrovent HFA in relation to other inhaled drugs.
Use only as prescribed
Remind patients that Atrovent HFA (Ipratropium Bromide) should be used consistently as prescribed throughout the course of therapy.
Preparation for use and priming
Instruct patients that priming Atrovent HFA is essential to ensure appropriate content of the medication in each actuation. Patients do not have to shake the canister with this drug before use.
B1 - Australia
B - United States (No evidence of risk in humans)
Salts and other forms:
Ipratropium Bromide Anhydrous
Ipratropium Bromide Monohydrate
Synonyms, international and chemical names:
Brometo de Ipratropio
Bromuro de Ipratropio
Ipratropium Br H2O
Brands, generics, trade names:
Aerotrop - Pablo Cassara Laboratorios
Aerovent - Teva
Alovent - Boehringer Ingelheim
Apo-Ipravent - Apotex
Atem - Chiesi
Atronase - Boehringer Ingelheim
Atrovent - Boehringer Ingelheim
Atrovent CFC-Free - Boehringer Ingelheim
Atrovent Forte - Boehringer Ingelheim
Atrovent HFA - Boehringer Ingelheim
Atrovent Inhaler CFC-Free - Boehringer Ingelheim
Atrovent-LS - Boehringer Ingelheim
Atrovent-N - Boehringer Ingelheim, DKSH
Atrovent-Nasal - Boehringer Ingelheim
Atrovent UDV - Boehringer Ingelheim
Atrovent Unit Dose - Boehringer Ingelheim, DKSH
Ipranase - Cipla
Ipratrin - Alphapharm
Ipratropium Bromide - Alpharma, Arrow Generiques, Bausch and Lomb, DEY Laboratories, IVAX, Mayne Pharma, Merck, Mylan, Teva
Ipravent - Cipla
Itrop - Boehringer Ingelheim
Mylan-Ipratropium - Mylan
PMS-Ipratropium - Pharmascience
Ratio-Ipratropium - Ratiopharm
Respontin - GlaxoSmithKline, Allen & Hanburys
Rhinovent - Boehringer Ingelheim
Rinatec - Boehringer Ingelheim
Steri-Neb Ipratropium - IVAX, Dynamed Pharmaceuticals, Norton Healthcare
APIs used in medicine in combinations with ipratropium bromide:
Here is a list of popular medications containing ipratropium bromide as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
|Trade name of the drug
||Pharmaceutical forms and doses
||Solution; Inhalation; Ipratropium Bromide 0.25 mg / ml
||Aerosol, Metered-Dose; Inhalation; Ipratropium Bromide 18 mcg / doseAerosol, Metered-Dose; Inhalation; Ipratropium Bromide 21 mcg / doseAerosol, Metered-Dose; Inhalation; Ipratropium Bromide 42 mcg / doseSolution; Inhalation; Ipratropium Bromide 125 mcg / mlSolution; Inhalation; Ipratropium Bromide 20 mcg / doseSolution; Inhalation; Ipratropium Bromide 0.25 mg / mlSolution; Inhalation; Ipratropium Bromide 500 mcg / mlSolution; Nasal; Ipratropium Bromide 0.3%
||Boehringer IngelheimAgencia Lei Va HongDiethelmDKSHIstituto de AngeliMetro Drug DistributionTeijinZuellig Pharma
||Solution; Inhalation; Ipratropium Bromide 20 mcg / dose
||Solution; Inhalation; Ipratropium Bromide 0.25 mg / ml
||Spray; Nasal; Ipratropium Bromide 22 mcg / doseSpray; Nasal; Ipratropium Bromide 44 mcg / dose
||Capsules; Inhalation; Ipratropium Bromide Monohydrate 40 mcgInjectable; Injection; Ipratropium Bromide Monohydrate 250 mcg / mlSolution; Inhalation; Ipratropium Bromide Monohydrate 250 mcg / mlSpray, Metered-Dose; Inhalation; Ipratropium Bromide Monohydrate 20 mcg / dose
||CiplaHind WingLBS LaboratoryPfizer
Ipratropium Bromide main article on Wikipedia: https://en.wikipedia.org/wiki/Ipratropium_bromide
Ipratropium compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Ipratropium
Ipratropium Bromide compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Ipratropium-bromide
Ipratropium medicine on DrugBank: https://go.drugbank.com/drugs/DB00332
Ipratropium Bromide Monohydrate on DrugBank: https://go.drugbank.com/salts/DBSALT000208
Ipratropium Oral Inhalation FAQ on MedlinePlus (revised 12/15/2017): https://medlineplus.gov/druginfo/meds/a695021.html
Ipratropium Nasal Spray FAQ on MedlinePlus (revised 04/15/2018): https://medlineplus.gov/druginfo/meds/a618013.html
Ipratropium Bromide solution drug label info on DailyMed (revised January 11, 2021): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Ipratropium Bromide spray drug label info on DailyMed (revised June 14, 2016): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Atrovent (Ipratropium Bromide) metered spray drug label info on DailyMed (revised September 10, 2010): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
Atrovent HFA (Ipratropium Bromide) aerosol metered drug label info on DailyMed (revised January 19, 2021): https://dailymed.nlm.nih.gov/dailymed/lookup...
Ipratropium Bromide containing drugs on Drugs-About.com: https://drugs-about.com/ing/ipratropium-bromide.html
Ipratropium Bromide for sale on Pharma Doctor: https://pharma-doctor.com/ipratropium-bromide.html
Atrovent HFA (Ipratropium Bromide) inhalation aerosol for oral inhalation official prescribing information and instructions for use from the U.S. FDA (revised 2012): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Atrovent (Ipratropium Bromide) nasal spray 0.06% official prescribing information and patient's instructions for use from the U.S. FDA (revised Nov 14, 2002): https://www.accessdata.fda.gov/drugsatfda_docs/label...
Atrovent HFA (Ipratropium Bromide) inhalation aerosol for oral inhalation use prescribing information and instructions for use from Boehringer Ingelheim pharmaceutical company (revised 02/2020): https://docs.boehringer-ingelheim.com/Prescribing%20Information/...
Atrovent Nasal and Atrovent Nasal Forte (Ipratropium Bromide) spray in pump-activated, metered dose containers product information from GP2U TeleHealth (15 June 2010): https://gp2u.com.au/static/pdf/A/...
Atrovent HFA (Ipratropium Bromide) inhalation aerosol official website: https://www.atrovent.com/
Ipravent (Ipratropium Bromide) inhalation solution consumer medicine information on NPS MedicineWise (revised May 2012): https://www.nps.org.au/assets/medicines/...
Atrovent Inhaler (Ipratropium Bromide) CFC-Free 20 micrograms/actuation pressurised inhalation solution package information leaflet from Medicines.org.uk (revised November 2020): https://www.medicines.org.uk/emc/files/pil.61.pdf
Revised: July 2021
Home | La maladie | Les symptômes | Les facteurs déclenchants | La qualité de vie | L'impact sur l'asthme | L'asthme chez l'enfant | Le traitement | Auto-test | Liens utiles | Confidentialité
Copyright © 1995 - 2021 Merck & Co., Inc. All Rights Reserved.